Moderna (MRNA.US) — stock surged over 17% in response to the news that AstraZeneca’s (AZN.US) CEO said the company would run another trial on its coronavirus vaccine candidate amid questions over the drug’s effectiveness. Meanwhile Moderna's vaccine has already posted outstanding results in its late-stage trial. The company, in turn, is expected to seek an Emergency Use Authorization from the Food and Drug Administration within the next few days. Other drugmaker’s Pizer (PFE.US) and BioNTech (BNTX.US), which are also working on their own vaccine, gained 1.7% and 4.4%, respectively.
Moderna (MRNA.US) stock launched today’ s session with a bullish price gap and painted fresh all-time high at $130.00. However bulls failed to uphold momentum and price pulled back to the $119.27 level. Source: xStation5
Trump’s plan for Strait of Hormuz fails to stop gains in oil price, as investors pause European sell off
Paramount Skydance shares under pressure after S&P warning
Broadcom as the Last of the Big Tech. What Can Markets Expect from the Earnings?
Nvidia Faces New H200 Limits in China
This content has been created by XTB S.A. This service is provided by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, entered in the register of entrepreneurs of the National Court Register (Krajowy Rejestr Sądowy) conducted by District Court for the Capital City of Warsaw, XII Commercial Division of the National Court Register under KRS number 0000217580, REGON number 015803782 and Tax Identification Number (NIP) 527-24-43-955, with the fully paid up share capital in the amount of PLN 5.869.181,75. XTB S.A. conducts brokerage activities on the basis of the license granted by Polish Securities and Exchange Commission on 8th November 2005 No. DDM-M-4021-57-1/2005 and is supervised by Polish Supervision Authority.
